Lenalidomide
Other / unclassified targets CRBN, IKZF1, IRF4, TNF via inhibition
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (8) | US (FDA) | REVLIMID | — | 2006-06-29 – 2019-05-28 | fda.gov ↗ |
| Approved | EU (EMA) | Revlimid | — | 2007-06-14 | europa.eu ↗ |
| Approved | US (FDA) | REVLIMID | — | 2005-12-27 | fda.gov ↗ |
Trials 891 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT06209606 | Dec 2022 → May 2026 overdue | plasma cell myeloma | Oncotherapeutics | Recruiting | No outcome recorded |
| Phase 0 | NCT03631043 | Dec 2018 → Dec 2025 | smoldering plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT02921893 | Oct 2016 → Apr 2022 | POEMS syndrome, plasmacytoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT00704691 | Jun 2008 → Jul 2009 | adult T-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified +1 | University of Alabama at Birmingham | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT00434239 | Feb 2007 → May 2011 | myelodysplastic syndrome | Peter MacCallum Cancer Centre, Australia | Unknown | No outcome recorded |
| Phase 1155 trials · 1 met primary · 2 missed | ||||||
| Phase 1 | NCT07341867 | Aug 2026 → Mar 2028 expected | plasma cell myeloma, triple-negative breast carcinoma | Andrew Hantel, MD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06768489 | Dec 2024 → Jan 2029 expected | AL amyloidosis, smoldering plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06015880 | May 2024 → Jun 2027 expected | high grade B-cell lymphoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT06192888 | Jan 2024 → Jan 2028 expected | mantle cell lymphoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06547944 | Jan 2024 → Dec 2025 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05867030 | Jul 2023 → Aug 2029 | follicular lymphoma | Innovent Biologics (Suzhou) Co. Ltd. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT05641324 | Feb → Jul 2023 | plasma cell myeloma | Anaveon AG | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05556616 | Jan 2023 → Jun 2024 | plasma cell myeloma | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04635683 | Sep 2022 → Dec 2023 | MALT lymphoma, Waldenstrom macroglobulinemia, follicular lymphoma, mantle cell lymphoma +2 | Yazeed Sawalha | Withdrawn | No outcome recorded |
| Phase 1 | NCT05137054 | Aug 2022 → Mar 2028 expected | plasma cell myeloma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Show all 155 trials opens the full record — a long page | ||||||
| Phase 1/2140 trials · 5 met primary · 3 missed | ||||||
| Phase 1/2 | NCT07384624 | Apr 2026 → Jun 2028 expected | HIV infectious disease | Erasmus Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07133763 | Sep 2025 → Sep 2027 expected | Epstein-Barr virus-associated lymphoproliferative disorder | The Affiliated Hospital of Xuzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07133776 | Sep 2025 → Sep 2027 expected | Epstein-Barr virus infection | The Affiliated Hospital of Xuzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06892522 | Jun 2025 → Feb 2036 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06762431 | Nov 2024 → Mar 2026 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | Vitebsk Regional Clinical Cancer Centre | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT06240520 | Apr 2024 → May 2025 | HIV infectious disease | Erasmus Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT05583617 | Nov 2023 → Jul 2028 expected | plasma cell myeloma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06087653 | Oct 2023 → May 2026 overdue | plasma cell myeloma | Starton Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05861050 | Aug 2023 → Feb 2027 | mantle cell lymphoma | City of Hope Medical Center | Suspended | No outcome recorded |
| Phase 1/2 | NCT05626322 | Aug 2023 → Aug 2024 | diffuse large B-cell lymphoma | Pfizer | Terminated | No outcome recorded Stop: Enrollment |
| Show all 140 trials opens the full record — a long page | ||||||
| Phase 2465 trials · 16 met primary · 9 missed | ||||||
| Phase 2 | NCT07605416 | Apr 2027 → Nov 2032 expected | plasma cell leukemia | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT07029776 | Mar 2027 → Apr 2030 expected | plasma cell myeloma | University of Arkansas | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07814001 | Dec 2026 → Jul 2028 expected | T-cell/histiocyte rich large B cell lymphoma, high grade B-cell lymphoma, large B-cell lymphoma | The Lymphoma Academic Research Organisation | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07830485 | Oct 2026 → Apr 2029 expected | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07828522 | Oct 2026 → Oct 2027 expected | plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07839247 | Sep 2026 → Oct 2027 expected | primary central nervous system lymphoma | Xiaohui Ren | Recruiting | No outcome recorded |
| Phase 2 | NCT07652905 | Sep 2026 → Jun 2029 expected | plasma cell leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT07639138 | Aug 2026 → Jun 2028 expected | hepatocellular carcinoma | Shunda Du | Recruiting | No outcome recorded |
| Phase 2 | NCT06348147 | Jul 2026 → May 2027 | disease related to hematopoietic stem cell transplant, plasma cell myeloma | UNC Lineberger Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT07560449 | Jun 2026 → Jun 2028 expected | plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Show all 465 trials opens the full record — a long page | ||||||
| Phase 2/310 trials · 2 missed | ||||||
| Phase 2/3 | NCT07732712 | Jan 2027 → Dec 2028 expected | plasma cell myeloma | The Affiliated People's Hospital of Ningbo University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07428369 | Jun 2026 → May 2038 | plasma cell myeloma | Regeneron Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/3 | NCT07095452 | Jan 2026 → Sep 2040 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07068165 | Jul 2025 → Jul 2028 expected | immunoglobulin G4-related sclerosing disease | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03759093 | Sep 2023 → Sep 2025 | plasma cell myeloma | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2/3 | NCT05665140 | Feb 2023 → Aug 2027 expected | plasma cell myeloma | University Hopsital Schleswig Holstein Campus Lübeck | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02145598 | Aug 2013 → Dec 2017 | plasma cell myeloma | Dr. med. Lars-Olof Muegge | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT01197560 | Sep 2010 → Jul 2013 | diffuse large B-cell lymphoma | Celgene Corporation | Completed | Missed primary |
| Phase 2/3 | NCT00120120 | Jan 2005 → Oct 2007 | radiculopathy | Celgene Corporation | Completed | Missed primary |
| Phase 2/3 | NCT00055562 | Jan 2003 → Dec 2004 | melanoma, metastatic neoplasm | Celgene Corporation | Completed | No outcome recorded |
| Phase 379 trials · 22 met primary · 12 missed | ||||||
| Phase 3 | NCT07649525 | Jul 2026 → Jun 2033 expected | plasma cell leukemia, plasma cell myeloma | University of Leeds | Recruiting | No outcome recorded |
| Phase 3 | NCT06965244 | Oct 2025 → Feb 2029 expected | cutaneous lupus erythematosus | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06918002 | Jul 2025 → May 2036 expected | plasma cell myeloma | Intergroupe Francophone du Myelome | Recruiting | No outcome recorded |
| Phase 3 | NCT06508658 | Aug 2024 → Mar 2028 expected | diffuse large B-cell lymphoma | Genmab | Active not recruiting | Met primary |
| Phase 3 | NCT06284122 | Jun 2024 → Nov 2028 expected | follicular lymphoma | The Lymphoma Academic Research Organisation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06187441 | May 2024 → Jan 2031 expected | plasma cell myeloma | HOVON Foundation | Recruiting | No outcome recorded |
| Phase 3 | NCT06521255 | May 2024 → Sep 2028 expected | diffuse large B-cell lymphoma | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06191744 | Feb 2024 → Nov 2037 expected | follicular lymphoma | Genmab | Recruiting | No outcome recorded |
| Phase 3 | NCT06045806 | Oct 2023 → Aug 2025 overdue | plasma cell myeloma | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05561387 | Oct 2023 → May 2031 expected | plasma cell myeloma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT06006117 | Sep 2023 → Sep 2027 expected | marginal zone lymphoma | The Lymphoma Academic Research Organisation | Recruiting | No outcome recorded |
| Phase 3 | NCT05429268 | Dec 2022 → Mar 2026 overdue | diffuse large B-cell lymphoma, large B-cell lymphoma | Incyte Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05558319 | Nov 2022 → Apr 2027 expected | plasma cell myeloma | PETHEMA Foundation | Recruiting | No outcome recorded |
| Phase 3 | NCT05243797 | Sep 2022 → Apr 2028 expected | plasma cell myeloma | European Myeloma Network B.V. | Recruiting | No outcome recorded |
| Phase 3 | NCT05351346 | Jun 2022 → Jun 2026 | diffuse large B-cell lymphoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05179733 | Mar 2022 → Dec 2025 | diffuse large B-cell lymphoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04824092 | May 2021 → Sep 2026 overdue | diffuse large B-cell lymphoma | Incyte Corporation | Active not recruiting | Met primary |
| Phase 3 | NCT04490707 | Sep 2020 → Dec 2022 | acute myeloid leukemia | Ge Zheng | Unknown | No outcome recorded |
| Phase 3 | NCT03993912 | Oct 2019 → Aug 2026 | plasma cell myeloma | University Hospital, Lille | Completed | Met primary |
| Phase 3 | NCT04084626 | Sep 2019 → Jul 2022 | Epstein-Barr virus infection | Beijing Friendship Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04071457 | Aug 2019 → Sep 2032 expected | plasma cell myeloma | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03836014 | Jul 2019 → Jul 2026 overdue | plasma cell myeloma | Assistance Publique - Hôpitaux de Paris | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03651128 | Apr 2019 → Apr 2026 | plasma cell myeloma | Celgene Corporation | Completed | Met primary |
| Phase 3 | NCT04298372 | Feb 2019 → Nov 2021 | AL amyloidosis | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03742297 | Oct 2018 → Jul 2023 overdue | plasma cell myeloma | PETHEMA Foundation | Active not recruiting | Met primary |
| Phase 3 | NCT04287660 | Oct 2017 → Jan 2023 | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 3 | NCT02544308 | Mar 2017 → Apr 2026 overdue | primary plasmacytoma of the bone | University College, London | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02516423 | Nov 2016 → Sep 2024 | solitary osseous plasmacytoma | Alliance for Clinical Trials in Oncology | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02516696 | Feb 2016 → Jun 2022 | plasma cell myeloma | Weill Medical College of Cornell University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02285062 | Feb 2015 → Mar 2019 | diffuse large B-cell lymphoma | Celgene Corporation | Completed | Missed primary |
| Phase 3 | NCT02128061 | Aug 2014 → Nov 2018 | diffuse large B-cell lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 3 | NCT02155634 | Jul 2014 → Apr 2017 | monoclonal paraproteinemia disease, plasma cell myeloma | Celgene Corporation | Withdrawn | No outcome recorded |
| Phase 3 | NCT02215980 | Jul 2014 → Jul 2022 | plasma cell myeloma | Fondazione EMN Italy Onlus | Completed | Met primary |
| Phase 3 | NCT02390869 | May 2014 → Jan 2023 overdue | follicular lymphoma | Fondazione Italiana Linfomi - ETS | Active not recruiting | Missed primary |
| Phase 3 | NCT02112175 | Apr 2014 → Oct 2020 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01996865 | Apr 2014 → May 2024 | non-Hodgkin lymphoma | Celgene Corporation | Completed | Missed primary |
| Phase 3 | NCT01863550 | Dec 2013 → Dec 2026 expected | plasma cell myeloma | ECOG-ACRIN Cancer Research Group | Active not recruiting | Missed primary |
| Phase 3 | NCT01938001 | Nov 2013 → Jun 2018 | non-Hodgkin lymphoma | Celgene Corporation | Completed | Met primary |
| Phase 3 | NCT01865110 | Nov 2013 → Nov 2020 | mantle cell lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 3 | NCT01556776 | Jul 2012 → Mar 2016 | B-cell chronic lymphocytic leukemia | German CLL Study Group | Completed | Met primary |
| Phase 3 | NCT01685814 | May 2012 → Sep 2016 | — | Wuerzburg University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01650701 | Feb 2012 → May 2017 | follicular lymphoma | The Lymphoma Academic Research Organisation | Completed | Missed primary |
| Phase 3 | NCT01476787 | Dec 2011 → Apr 2024 | follicular lymphoma | Celgene Corporation | Completed | Missed primary |
| Phase 3 | NCT01169337 | Jan 2011 → Jan 2019 overdue | light chain deposition disease, smoldering plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | Met primary |
| Phase 3 | NCT01208766 | Jan 2011 → Dec 2020 | plasma cell myeloma | HOVON Foundation | Completed | Met primary |
| Phase 3 | NCT01191060 | Oct 2010 → Nov 2018 | plasma cell myeloma | University Hospital, Toulouse | Completed | Met primary |
| Phase 3 | NCT01208662 | Sep 2010 → Feb 2022 overdue | plasma cell myeloma | Paul Richardson, MD | Active not recruiting | Met primary |
| Phase 3 | NCT01098656 | Jul 2010 → Sep 2013 | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02354313 | May 2010 → Dec 2017 | mantle cell lymphoma | Fondazione Italiana Linfomi - ETS | Unknown | Met primary |
| Phase 3 | NCT01021423 | Apr 2010 → Mar 2011 | mantle cell lymphoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT01621672 | Apr 2010 → Aug 2014 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 3 | NCT01029262 | Jan 2010 → Mar 2013 | anemia | Celgene Corporation | Completed | Mixed |
| Phase 3 | NCT01243476 | Jan 2010 → Jun 2022 | myelodysplastic syndrome | Fundación General de la Universidad de Salamanca | Completed | Met primary |
| Phase 3 | NCT00988208 | Nov 2009 → Jan 2012 | prostate cancer | Celgene Corporation | Completed | Missed primary |
| Phase 3 | NCT00910910 | Oct 2009 → Mar 2014 | B-cell chronic lymphocytic leukemia | Celgene Corporation | Completed | Missed primary |
| Phase 3 | NCT01093196 | Oct 2009 → Nov 2012 | plasma cell myeloma | Fondazione EMN Italy Onlus | Completed | Missed primary |
| Phase 3 | NCT00928486 | Apr 2009 → Sep 2010 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00843882 | Apr 2009 → Jul 2019 overdue | anemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | National Cancer Institute (NCI) | Active not recruiting | Met primary |
| Phase 3 | NCT00891384 | Apr 2009 → Jun 2017 | plasma cell myeloma | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | Completed | No outcome recorded |
| Phase 3 | NCT01122472 | Apr 2009 → Jun 2016 | diffuse large B-cell lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 3 | NCT00774345 | Jan 2009 → Oct 2020 | B-cell chronic lymphocytic leukemia | Celgene Corporation | Completed | Missed primary |
| Phase 3 | NCT00689936 | Aug 2008 → Jul 2016 | plasma cell myeloma | Celgene Corporation | Completed | Met primary |
| Phase 3 | NCT00644228 | Jul 2008 → Nov 2015 overdue | plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | Met primary |
| Phase 3 | NCT00602641 | Feb 2008 → Jan 2014 overdue | plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | Missed primary |
| Phase 3 | NCT00522392 | Sep 2007 → Aug 2012 | plasma cell myeloma | National Cancer Institute (NCI) | Terminated | Missed primary Stop: Enrollment |
| Phase 3 | NCT00478777 | Mar → Nov 2007 | refractory plasma cell neoplasm | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00405756 | Jan 2007 → Nov 2009 | plasma cell myeloma | Celgene Corporation | Completed | Met primary |
| Phase 3 | NCT00420849 | Nov 2006 → Oct 2009 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00430365 | Jun 2006 → Sep 2017 | plasma cell myeloma | University Hospital, Toulouse | Completed | Met primary |
| Phase 3 | NCT00179647 | Sep 2005 → Dec 2008 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00179621 | Jul 2005 → Jun 2008 | myelodysplastic syndrome | Celgene Corporation | Completed | Met primary |
| Phase 3 | NCT00114101 | Dec 2004 → Dec 2012 overdue | smoldering plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | Met primary |
| Phase 3 | NCT00098475 | Nov 2004 → Nov 2008 overdue | plasma cell myeloma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00064038 | Nov 2004 → Oct 2008 | plasma cell myeloma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00093028 | Jan 2004 → Jan 2006 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 3 | NCT00622336 | Apr 2003 → Nov 2013 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00424047 | Jan 2003 → Nov 2005 | plasma cell myeloma | Celgene Corporation | Completed | Met primary |
| Phase 3 | NCT00056160 | Jan 2003 → Nov 2005 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00057616 | Oct 2002 → Jul 2005 | melanoma, metastatic malignant neoplasm | Celgene Corporation | Completed | No outcome recorded |
| Phase 417 trials | ||||||
| Phase 4 | NCT07709884 | Jul 2026 → Dec 2028 expected | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06409702 | Jun 2024 → Nov 2027 expected | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 4 | NCT06004765 | Aug 2023 → Aug 2024 | myelodysplastic syndrome | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05598580 | Nov 2022 → May 2024 | HIV infectious disease | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05722405 | Jul 2022 → Jun 2026 overdue | plasma cell myeloma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 4 | NCT05183139 | Jun 2022 → Dec 2026 | plasma cell myeloma | Takeda | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04842318 | Mar 2021 → Mar 2023 | follicular lymphoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04361643 | Oct 2020 → Aug 2021 | COVID-19 | Hospital Universitario Getafe | Unknown | No outcome recorded |
| Phase 4 | NCT04217967 | Sep 2019 → Jun 2024 | plasma cell myeloma | Peking Union Medical College Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03934684 | Sep 2019 → Mar 2023 | refractory plasma cell neoplasm | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT04040491 | Sep 2019 → Dec 2020 | peripheral T-cell lymphoma, not otherwise specified | Mingzhi Zhang | Unknown | No outcome recorded |
| Phase 4 | NCT04152577 | Jun 2019 → Oct 2021 | B-cell non-Hodgkin lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04038411 | Apr 2019 → Apr 2021 | mature T-cell and NK-cell non-Hodgkin lymphoma | Mingzhi Zhang | Unknown | No outcome recorded |
| Phase 4 | NCT03908138 | Mar 2019 → Dec 2021 | plasma cell myeloma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03829371 | Jan 2019 → Jan 2027 expected | plasma cell myeloma | University of Turin, Italy | Active not recruiting | No outcome recorded |
| Phase 4 | NCT01198054 | Jan 2011 → Feb 2013 | acute myeloid leukemia | PETHEMA Foundation | Terminated | No outcome recorded |
| Phase 4 | NCT01408199 | Jan → Aug 2010 | cutaneous lupus erythematosus | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase not applicable18 trials | ||||||
| — | NCT07299331 | Jan 2026 → Apr 2031 expected | marginal zone lymphoma | Zhengzhou University | Not yet recruiting | No outcome recorded |
| — | NCT06697483 | Dec 2024 → Dec 2026 expected | plasma cell myeloma | Peking University People's Hospital | Recruiting | No outcome recorded |
| — | NCT07072221 | Nov 2024 → Aug 2029 expected | peripheral T-cell lymphoma, not otherwise specified | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| — | NCT07184424 | May 2023 → Apr 2025 | hepatocellular carcinoma | Beijing Tsinghua Chang Gung Hospital | Completed | No outcome recorded |
| — | NCT05784987 | Apr 2023 → Jan 2024 | diffuse large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT05449548 | Apr 2023 → Dec 2026 expected | ulcerative stomatitis | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| — | NCT05477797 | Feb 2023 → Jan 2026 | — | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT05488327 | Aug 2022 → Aug 2023 | dermatomyositis | Jiangxi Provincial People's Hopital | Unknown | No outcome recorded |
| — | NCT05797948 | Jul 2022 → Jun 2024 | B-cell non-Hodgkin lymphoma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| — | NCT05058755 | Sep 2021 → Dec 2022 | extranodal nasal NK/T cell lymphoma | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| — | NCT04432402 | Jun 2020 → Dec 2022 | diffuse large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT04319601 | Mar 2020 → Mar 2022 | angioimmunoblastic T-cell lymphoma, chemotherapy-induced toxicity | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| — | NCT04008888 | Jan 2018 → Jan 2020 | chromosome 17p deletion, extramedullary soft tissue plasmacytoma, plasma cell leukemia, plasma cell myeloma | Institute of Hematology & Blood Diseases Hospital, China | Unknown | No outcome recorded |
| — | NCT01927718 | Jan 2014 → Nov 2016 | plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| — | NCT01050790 | Jan 2010 → Aug 2014 | plasma cell myeloma | Virginia Commonwealth University | Completed | No outcome recorded |
| — | NCT01649791 | Jan 2010 → May 2012 | B-cell chronic lymphocytic leukemia | Roswell Park Cancer Institute | Terminated | No outcome recorded |
| — | NCT00890552 | Apr 2009 → Aug 2012 | amyloidosis, leukemia | Stanford University | Completed | No outcome recorded |
| — | NCT00633945 | Nov 2007 → Jul 2009 | cutaneous lupus erythematosus | University of Pennsylvania | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT02368301 | — | plasma cell myeloma | Bristol-Myers Squibb | No longer available | No outcome recorded |
| — | NCT02856438 | — | plasma cell myeloma | Bristol-Myers Squibb | No longer available | No outcome recorded |
| Comparator or background therapy227 trials | ||||||
| Phase 0 | NCT05846880 Background | Dec 2024 → May 2028 expected | plasma cell myeloma | Amany Keruakous, MD, MS. | Recruiting | No outcome recorded |
| Phase 0 | NCT04049864 Background | Jan 2019 → Dec 2023 | neuroblastoma | Belarusian Research Center for Pediatric Oncology, Hematology and Immunology | Unknown | No outcome recorded |
| Phase 0 | NCT01861340 Background | May 2014 → Apr 2016 | plasma cell myeloma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 0 | NCT01537861 Background | Jun 2012 → Feb 2014 | plasma cell myeloma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT07697339 Comparator | Jul 2026 → Aug 2027 expected | mantle cell lymphoma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Show all 227 trials opens the full record — a long page | ||||||
Press releases naming this drug 83 releases
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 1,133 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lenalidomide | “APG-2575+ Lenalidomide administered at a dose of 25 mg orally (PO) on Days 1 through 21 of each 28-day cycle, dexamethasone will be administered at a dose of 40 mg (or 20 mg...” NCT04942067 ↗1092“The patients will be given Lenalidomide (25mg/d, po, D1-10, every 21 days for total 6 courses) combined with Rituximab (375mg/m2 d0, every 21 days for total 6 courses) followed...” NCT04842318 ↗ “The purpose of this study is to find out whether Tec-RVd (teclistamab, lenalidomide, bortezomib, and dexamethasone) after 3 treatment Cycles of Dara-RVd (daratumumab,...” NCT07099391 ↗ “Eligible patients with transplant-eligible relapsed/refractory DLBCL will receive 2-4 cycles (21 days per cycle) of tafasitamab combined with lenalidomide and standard...” NCT07621406 ↗ “Using the combined regimen of CHiR (chidamide, zanubrutinib, and lenalidomide) to treat newly diagnosed elderly patients with MYC- and BCL2-expressing positive diffuse large...” NCT06764017 ↗ “Targeting Bruton's tyrosine kinase (BTK), the novel BTK inhibitor zanubrutinib (highly selective, low toxicity) combined with obinutuzumab (enhanced antibody-dependent...” NCT07165769 ↗ “Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Topotecan In Subjects...” NCT00179712 ↗ “Induction therapy consist of bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab, lenalidomide, and dexamethasone (DRd) or daratumumab, bortezomib, lenalidomide,...” NCT07149857 ↗ “induction therapy using the combination of dexamethasone, lenalidomide (revlimid), daratumumab (Darzalex) and carfilzomib (Kyprolis) to treat patients with newly diagnosed...” NCT03224507 ↗ “Patients received rituximab (375 mg/m2 intravenously on Day 1), lenalidomide (15 mg orally on Days 1-21), and chidamide (30 mg orally twice weekly) in 28-day cycles for up to 6 cycles.” PMID 42124356 ↗ May 2026 “A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Recurrent Non-Small Cell Lung Cancer” NCT00179686 ↗ |
| Known as | CC-5013 | “This is a randomized phase III trial of CC-5013 (lenalidomide, NSC-703813) and low dose dexamethasone (LLD) versus bortezomib (PS-341, NSC-681239), lenalidomide and low dose...” NCT01530594 ↗38“A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy in Subjects With Previously...” NCT01476787 ↗ “A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Recurrent Non-Small Cell Lung Cancer” NCT00179686 ↗ “In a phase I study heavily pretreated patients with relapsed or refractory myeloma were treated with CC-5013 (RevlimidTM, lenalidomide).” NCT00306813 ↗ “A Phase I Study of SGN-40 (Anti-huCD40 mAb), Lenalidomide (Revlimid®, cc 5013), and Dexamethasone in Patients With Multiple Myeloma (MM)” NCT00525447 ↗ “Phase I Trial of Daily Lenalidomide (CC-5013, Revlimid™) and Docetaxel Given Every Three Weeks in Patients With Advanced Solid Tumors” NCT00253344 ↗ “Lenalidomide (Revlimid® CC-5013) with Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma” NCT00179725 ↗ “single-agent lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma” NCT00413036 ↗ “Lenalidomide (CC-5013) is a structural derivative of thalidomide, with antiangiogenic and immunomodulatory effects.” PMID 18161005 ↗ Dec 2007 “Lenalidomide (CC-5013, Revlimid; Celgene Corporation) is an oral thalidomide analogue with anti-cancer activity.” NCT00322985 ↗ “Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF)” NCT00352794 ↗ |
| Known as | CDC-501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00044018 ↗ |
| Known as | Leavdo | “Lenalidomide [Leavdo®]” NCT04604028 ↗ |
| Known as | LEN | “We investigated whether treatment with lenalidomide (LEN), which augments erythropoietin receptor signaling in vitro, can restore and improve hemoglobin response to epoetin...” PMID 33439748 ↗ Jan 202112“This phase 1b study (NCT02431208) evaluated the safety and efficacy of the anti-programmed death-ligand 1 monoclonal antibody atezolizumab (Atezo) alone or in combination with...” PMID 37559718 ↗ Jul 2023 “PURPOSE: Single-cycle melphalan 200 mg/m2 and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved progression-free...” PMID 30653422 ↗ Jan 2019 “We have previously demonstrated the anti-multiple myeloma effects of RUX alone and in combination with the immunomodulatory agent lenalidomide (LEN) and glucocorticosteroids...” PMID 38643346 ↗ Apr 2024 “The CD30-targeted, antibody-drug conjugate brentuximab vedotin (BV) and the immunomodulator lenalidomide (Len) have demonstrated promising activity as single agents in this population.” PMID 34780623 ↗ Mar 2022 “The Southwest Oncology Group conducted a randomized trial comparing lenalidomide (LEN) plus dexamethasone (DEX; n = 97) to placebo (PLC) plus DEX (n = 95) in newly diagnosed myeloma.” PMID 20876454 ↗ Sep 2010 “we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment for elderly patients with MCL.” PMID 27354719 ↗ Jun 2016 “the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the PAM axis with synergistic potential.” PMID 34320785 ↗ Jul 2022 “Lenalidomide (Len) and Dexamethasone (Dex) for 6 months followed by three donor lymphocyte infusions (DLIs)” NCT03413800 ↗ “Lenalidomide (LEN) and rituximab (RTX) have independently improved progression-free survival (PFS) in CLL” PMID 38856101 ↗ Jun 2024 “Ixazomib (IXA) in combination with lenalidomide (LEN) and low-dose dex (IRd)” NCT03651128 ↗ |
| Known as | Lenalidomide (REVLIMID) | “Lenalidomide (REVLIMID®)” NCT01191060 ↗4“Lenalidomide (REVLIMID®)” NCT01206205 ↗ “Lenalidomide (Revlimid)” NCT01307605 ↗ “Lenalidomide (Revlimid)” NCT01297764 ↗ “Lenalidomide: REVLIMID” NCT01185262 ↗ |
| Known as | lenalidomide capsules | “lenalidomide capsules” NCT07184424 ↗ |
| Known as | NSC #703813 | “This is a randomized phase III trial of CC-5013 (lenalidomide, NSC-703813) and low dose dexamethasone (LLD) versus bortezomib (PS-341, NSC-681239), lenalidomide and low dose...” NCT01530594 ↗1“A Phase II Trial of Lenalidomide (Revlimid (TM), CC-5013) (NSC #703813) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL)” NCT01145495 ↗ |
| Known as | Rev | “lenalidomide (Rev) in patients with MM.” PMID 22816680 ↗ Jul 2012 |
| Known as | Revlamid | “Revlamid® (Lenalidomide)” NCT01245673 ↗ |
| Known as | Revlimid | “A Multicentre Prospective Phase II Single Arm Trial Evaluating the Benefit of Therapy With Lenalidomide (Revlimid®) in Relapsed or Refractory Primary-cutaneous Large B-cell...” NCT01556035 ↗80“The purpose of the study is to assess the efficacy of the association of Lenalidomide (Revlimid) and R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, vincristine and...” NCT01393756 ↗ “Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment w/ Carfilzomib, Lenalidomide (Revlimid®) and Dexamethasone (CRD) in...” NCT01029054 ↗ “This is an open label, phase II study to evaluate the capacity of Rituximab (Mabthera®) plus Lenalidomide (Revlimid®) to induce objective responses in patients with Mucosa...” NCT01611259 ↗ “Evaluation of Lenalidomide (REVLIMID®) in Cutaneous LE: A Prospective, Non Controlled, Open Label Pilot Study to Evaluate the Off-Label Use of the FDA-approved Drug...” NCT00633945 ↗ “Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid®) With Topotecan In Subjects...” NCT00179712 ↗ “A Phase 2, Multi-Center, Randomized, Double-Blinded, Parallel Group Study of the Safety and Efficacy of Different Lenalidomide (REVLIMID®) Dose Regimens in Subjects With...” NCT00963105 ↗ “Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic...” NCT01754870 ↗ “The purpose of the study is to determine the recommended dose (RD) of lenalidomide (Revlimid) when administered in association with R-CHOP (rituximab (R), cyclophosphamide,...” NCT00901615 ↗ “The purpose of the first part is to find the highest dose of a drug called lenalidomide (Revlimid®) that can be given in combination with high dose melphalan without causing...” NCT01142232 ↗ “Phase 3B, Randomized Trail of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly...” NCT02112175 ↗ |
| Known as | Revlimid (lenalidomide) | “Revlimid (lenalidomide)” NCT01554852 ↗1“Revlimid (lenalidomide)” NCT00783367 ↗ |
| Known as | Revlimid for Lenalidomide | “Revlimid for Lenalidomide” NCT01270932 ↗ |
| Known as | RevlimidTM | “Lenalidomide (RevlimidTM ) and GM-CSF” NCT00939510 ↗ |
| Action | Inhibit | “inhibiting TNF-alfa secretion” NCT00396045 ↗ |
| Modality | Other / unclassified | “Lenalidomide is an immunomodulatory agent” PMID 28771673 ↗ Aug 2017 |
| Route | Oral | “Patients were treated on a modified Fibronacci dose escalation scheme with an oral daily dose of lenalidomide.” PMID 19451403 ↗ Jun 2009 |
| Target | TNF | “inhibiting TNF-alfa secretion” NCT00396045 ↗ |